Mink Therapeutics Inc
NASDAQ:INKT
Mink Therapeutics Inc
NASDAQ:INKT
Price:
10.28
USD
-8.05%
Market Cap:
$48.2m
Relative Value
There is not enough data to reliably calculate the relative value of INKT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INKT
Relative Value
Base Case
Not Available
Multiples Across Competitors
INKT Competitors Multiples
Mink Therapeutics Inc Competitors
Mink Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
47.3m USD | 0 | -3.8 | -3.2 | -3.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.3B USD | 6.4 | 94.1 | 15.5 | 21.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.3B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.7B USD | 6.2 | 21.3 | 13.2 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.8B USD | 10 | 30.5 | 23 | 24 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
